HRP20110094T8 - Solid preparation comprising alogliptin and pioglitazone - Google Patents

Solid preparation comprising alogliptin and pioglitazone

Info

Publication number: HRP20110094T8
Authority: HR; Croatia
Prior art keywords: pioglitazone; alogliptin; solid preparation; sugar; excipient
Prior art date: 2007-02-01

Application number

HR20110094T

Other languages

English (en)

Croatian (hr)

Inventor

Nakamura Kenji

Kiyoshima Kenichiro

Nomura Junya

Original Assignee

Takeda Pharmaceutical Company Limited

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-01

Filing date

2011-02-07

Publication date

2011-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39240362&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20110094(T8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-02-07 Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited

2011-03-31 Publication of HRP20110094T1 publication Critical patent/HRP20110094T1/hr

2011-07-31 Publication of HRP20110094T8 publication Critical patent/HRP20110094T8/xx

Links

LNTORSITGSWVNQ-DYYGGQLPSA-N 2-[[6-[(3r)-3-aminopiperidin-1-yl]-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile;5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1.C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCC[C@@H](N)C1 LNTORSITGSWVNQ-DYYGGQLPSA-N 0.000 title 1
239000007787 solid Substances 0.000 title 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 2
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 abstract 2
150000003839 salts Chemical class 0.000 abstract 2
150000005846 sugar alcohols Chemical class 0.000 abstract 2
ZSBOMTDTBDDKMP-UHFFFAOYSA-N 2-[[6-(3-aminopiperidin-1-yl)-3-methyl-2,4-dioxopyrimidin-1-yl]methyl]benzonitrile Chemical compound C=1C=CC=C(C#N)C=1CN1C(=O)N(C)C(=O)C=C1N1CCCC(N)C1 ZSBOMTDTBDDKMP-UHFFFAOYSA-N 0.000 abstract 1
229960005095 pioglitazone Drugs 0.000 abstract 1
239000008247 solid mixture Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HR20110094T 2007-02-01 2011-02-07 Solid preparation comprising alogliptin and pioglitazone HRP20110094T8 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2007023594		2007-02-01
PCT/JP2008/051900 WO2008093882A1 (en)	2007-02-01	2008-01-30	Solid preparation comprising alogliptin and pioglitazone

Publications (2)

Publication Number	Publication Date
HRP20110094T1 HRP20110094T1 (hr)	2011-03-31
HRP20110094T8 true HRP20110094T8 (en)	2011-07-31

Family

ID=39240362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20110094T HRP20110094T8 (en)	2007-02-01	2011-02-07	Solid preparation comprising alogliptin and pioglitazone

Country Status (39)

Country	Link
US (1)	US8637079B2 (xx)
EP (1)	EP2107905B1 (xx)
JP (1)	JP5284968B2 (xx)
KR (1)	KR101486091B1 (xx)
CN (1)	CN101646420B (xx)
AR (1)	AR065097A1 (xx)
AT (1)	ATE488227T1 (xx)
AU (1)	AU2008211981B2 (xx)
BR (1)	BRPI0807453B8 (xx)
CA (1)	CA2677201C (xx)
CL (1)	CL2008000279A1 (xx)
CR (1)	CR10992A (xx)
CY (1)	CY1111264T1 (xx)
DE (1)	DE602008003522D1 (xx)
DK (1)	DK2107905T3 (xx)
DO (1)	DOP2009000195A (xx)
EA (1)	EA015180B1 (xx)
EC (1)	ECSP099608A (xx)
ES (1)	ES2354397T3 (xx)
GE (1)	GEP20125410B (xx)
HK (1)	HK1138188A1 (xx)
HR (1)	HRP20110094T8 (xx)
IL (1)	IL200108A (xx)
JO (1)	JO2650B1 (xx)
MA (1)	MA31169B1 (xx)
ME (1)	ME01239B (xx)
MX (1)	MX2009008100A (xx)
MY (1)	MY147596A (xx)
NZ (1)	NZ579008A (xx)
PE (1)	PE20081663A1 (xx)
PL (1)	PL2107905T3 (xx)
PT (1)	PT2107905E (xx)
RS (1)	RS51592B (xx)
SI (1)	SI2107905T1 (xx)
TN (1)	TN2009000317A1 (xx)
TW (2)	TWI453041B (xx)
UA (1)	UA95828C2 (xx)
WO (1)	WO2008093882A1 (xx)
ZA (1)	ZA200905621B (xx)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en)	2004-02-18	2009-03-10	Boehringer Ingelheim International Gmbh	8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de)	2005-07-30	2007-02-08	Boehringer Ingelheim Pharma Gmbh & Co. Kg	8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CA2810522A1 (en)	2006-05-04	2007-11-15	Boehringer Ingelheim International Gmbh	Polymorphs
PE20080251A1 (es)	2006-05-04	2008-04-25	Boehringer Ingelheim Int	Usos de inhibidores de dpp iv
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
MY159203A (en)	2007-07-19	2016-12-30	Takeda Pharmaceuticals Co	Solid preparation comprising alogliptin and metformin hydrochloride
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
AR071175A1 (es)	2008-04-03	2010-06-02	Boehringer Ingelheim Int	Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante
UY32030A (es)	2008-08-06	2010-03-26	Boehringer Ingelheim Int	"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	Inibidor de dpp-4 e seu uso
BRPI0917675A2 (pt)	2008-08-15	2015-12-01	Boehringer Ingelheim Int	compostos orgânicos para cura de ferida
EP2344195A2 (en)	2008-09-10	2011-07-20	Boehringer Ingelheim International GmbH	Combination therapy for the treatment of diabetes and related conditions
UY32126A (es)	2008-09-25	2010-04-30	Takeda Pharmaceutical	Composición farmacéutica sólida
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
JP2012512848A (ja)	2008-12-23	2012-06-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	有機化合物の塩の形態
AR074990A1 (es)	2009-01-07	2011-03-02	Boehringer Ingelheim Int	Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es)	2009-01-29	2011-03-16	Boehringer Ingelheim Int	Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
KR20160143897A (ko)	2009-02-13	2016-12-14	베링거 인겔하임 인터내셔날 게엠베하	Ｄｐｐ－４ 억제제(리나글립틴)을 임의로 다른 당뇨병 치료제와 병용하여 포함하는 당뇨병 치료 약제
EA022349B1 (ru)	2009-02-13	2015-12-30	Бёрингер Ингельхайм Интернациональ Гмбх	Фармацевтическая композиция, включающая ингибитор sglt2, ингибитор дпп-iv и другой антидиабетический агент, и ее применение
BR112012012641A2 (pt)	2009-11-27	2020-08-11	Boehringer Ingelheim International Gmbh	TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA
US20130109703A1 (en)	2010-03-18	2013-05-02	Boehringer Ingelheim International Gmbh	Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
AU2011249771A1 (en) *	2010-05-05	2012-11-01	Boehringer Ingelheim International Gmbh	Pharmaceutical formulations comprising pioglitazone and linagliptin
CA2797310C (en)	2010-05-05	2020-03-31	Boehringer Ingelheim International Gmbh	Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
AU2011268940B2 (en)	2010-06-24	2015-05-21	Boehringer Ingelheim International Gmbh	Diabetes therapy
CN101912363A (zh) *	2010-07-29	2010-12-15	蔡海德	溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
AR083878A1 (es)	2010-11-15	2013-03-27	Boehringer Ingelheim Int	Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
UY33937A (es)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
US8962636B2 (en)	2011-07-15	2015-02-24	Boehringer Ingelheim International Gmbh	Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
EP2849755A1 (en)	2012-05-14	2015-03-25	Boehringer Ingelheim International GmbH	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
CN103877054B (zh) *	2012-12-21	2016-05-25	北大方正集团有限公司	一种苯甲酸阿格列汀片剂及其制备方法
CN103156819A (zh) *	2013-03-29	2013-06-19	山东罗欣药业股份有限公司	苯甲酸阿格列汀组合物片剂及其制备方法
WO2015128453A1 (en)	2014-02-28	2015-09-03	Boehringer Ingelheim International Gmbh	Medical use of a dpp-4 inhibitor
WO2016104643A1 (ja) *	2014-12-25	2016-06-30	田辺三菱製薬株式会社	糖尿病治療用固形製剤
WO2016202961A1 (en) *	2015-06-17	2016-12-22	H E X A L Aktiengesellschaft	Alogliptin formulation
CN108289849A (zh) *	2015-06-26	2018-07-17	韩国联合制药株式会社	莫沙必利与雷贝拉唑的复合制剂
CN105030719B (zh) *	2015-08-20	2018-07-20	杭州成邦医药科技有限公司	一种含有阿格列汀和吡格列酮的组合物
EP4233840A3 (en)	2016-06-10	2023-10-18	Boehringer Ingelheim International GmbH	Combinations of linagliptin and metformin
KR102485766B1 (ko)	2019-12-11	2023-01-09	한국유나이티드제약 주식회사	생체이용률이 향상된 피오글리타존 함유 약학조성물
CN113925838B (zh) *	2021-11-11	2022-11-11	乐普制药科技有限公司	一种依帕司他与西格列汀或其可药用盐的复方缓释片及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR240698A1 (es)	1985-01-19	1990-09-28	Takeda Chemical Industries Ltd	Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
EP0559702B1 (de)	1990-11-27	1994-12-28	Byk Gulden Lomberg Chemische Fabrik Gmbh	Retardzubereitung für urapidil
TWI238064B (en)	1995-06-20	2005-08-21	Takeda Chemical Industries Ltd	A pharmaceutical composition for prophylaxis and treatment of diabetes
JP2931811B2 (ja)	1997-06-03	1999-08-09	ユニコロイド株式会社	徐放性カプセル
US6030641A (en)	1997-06-03	2000-02-29	Uni Colloid Kabushiki Kaisha	Sustained release capsule and method for preparing the same
WO1998056359A2 (de)	1997-06-13	1998-12-17	Roland Bodmeier	Zusammensetzungen, die die wirkstofffreisetzung verzögern
DE19725911A1 (de)	1997-06-13	1998-12-17	Roland Prof Dr Bodmeier	Zusammensetzungen, die die Wirkstofffreisetzung verzögern
JP2000154137A (ja)	1998-09-18	2000-06-06	Takeda Chem Ind Ltd	徐放性経口製剤
AU5652199A (en)	1998-09-18	2000-04-10	Takeda Chemical Industries Ltd.	Sustained release oral preparations
AU5325200A (en)	1999-06-21	2001-01-09	Eli Lilly And Company	Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
AR030920A1 (es)	1999-11-16	2003-09-03	Smithkline Beecham Plc	Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
DK1741447T3 (da)	2000-01-21	2013-12-09	Novartis Ag	Kombinationer omfattende dipeptidylpeptidase-IV-inhibitorer og antidiabetiske midler
US6395767B2 (en)	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
GB0014969D0 (en)	2000-06-19	2000-08-09	Smithkline Beecham Plc	Novel method of treatment
US7078397B2 (en)	2000-06-19	2006-07-18	Smithkline Beecham Corporation	Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
US6573287B2 (en)	2001-04-12	2003-06-03	Bristo-Myers Squibb Company	2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
AR034517A1 (es) *	2001-06-21	2004-02-25	Astrazeneca Ab	Formulacion farmaceutica
UA74912C2 (en)	2001-07-06	2006-02-15	Merck & Co Inc	Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US8329217B2 (en) *	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
AU2003281181A1 (en)	2002-07-11	2004-02-02	Takeda Pharmaceutical Company Limited	Process for producing coated preparation
IN192749B (xx)	2002-11-15	2004-05-15	Ranbaxy Lab Ltd
JP4567340B2 (ja) *	2003-01-29	2010-10-20	武田薬品工業株式会社	被覆製剤の製造方法
US7976853B2 (en) *	2003-01-29	2011-07-12	Takeda Pharmaceutical Company Limited	Process for producing coated preparation
ES2556244T3 (es)	2003-10-31	2016-01-14	Takeda Pharmaceutical Company Limited	Preparación sólida que comprende pioglitazona, glimepirida y un éster de ácido graso de polioxietilensorbitán
JP4361461B2 (ja) *	2003-10-31	2009-11-11	武田薬品工業株式会社	固形製剤
DK3023095T3 (en)	2004-01-20	2018-08-20	Novartis Ag	Directly pressed wording and approach
CN102140090A (zh)	2004-03-15	2011-08-03	武田药品工业株式会社	二肽基肽酶抑制剂
JP2008517921A (ja)	2004-10-25	2008-05-29	ノバルティスアクチエンゲゼルシャフト	Ｄｐｐ−ｉｖ阻害剤、ｐｐａｒ抗糖尿病薬およびメトホルミンの組合わせ剤
GT200600218A (es)	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
HRP20140091T4 (hr)	2005-09-14	2021-12-24	Takeda Pharmaceutical Company Limited	Davanje inhibitora dipeptidil peptidaze
TW200745079A (en)	2005-09-16	2007-12-16	Takeda Pharmaceuticals Co	Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
BRPI0620020A2 (pt)	2005-12-22	2011-10-25	Takeda Pharmaceutical	preparação sólida, e, partìcula revestida
CA2635777A1 (en)	2005-12-28	2007-07-05	Takeda Pharmaceutical Company Limited	Combination therapy for diabetes

2008
- 2008-01-30 CL CL200800279A patent/CL2008000279A1/es unknown
- 2008-01-30 BR BRPI0807453A patent/BRPI0807453B8/pt active IP Right Grant
- 2008-01-30 PL PL08704473T patent/PL2107905T3/pl unknown
- 2008-01-30 ES ES08704473T patent/ES2354397T3/es active Active
- 2008-01-30 ME MEP-2011-167A patent/ME01239B/me unknown
- 2008-01-30 JP JP2009532078A patent/JP5284968B2/ja active Active
- 2008-01-30 MX MX2009008100A patent/MX2009008100A/es active IP Right Grant
- 2008-01-30 TW TW097103417A patent/TWI453041B/zh active
- 2008-01-30 DE DE602008003522T patent/DE602008003522D1/de active Active
- 2008-01-30 AR ARP080100381A patent/AR065097A1/es not_active Application Discontinuation
- 2008-01-30 ZA ZA200905621A patent/ZA200905621B/xx unknown
- 2008-01-30 RS RS20110080A patent/RS51592B/en unknown
- 2008-01-30 EP EP08704473A patent/EP2107905B1/en active Active
- 2008-01-30 AT AT08704473T patent/ATE488227T1/de active
- 2008-01-30 DK DK08704473.1T patent/DK2107905T3/da active
- 2008-01-30 NZ NZ579008A patent/NZ579008A/en unknown
- 2008-01-30 TW TW102128229A patent/TW201350143A/zh unknown
- 2008-01-30 MY MYPI20093188A patent/MY147596A/en unknown
- 2008-01-30 KR KR1020097017913A patent/KR101486091B1/ko active IP Right Review Request
- 2008-01-30 UA UAA200909031A patent/UA95828C2/ru unknown
- 2008-01-30 WO PCT/JP2008/051900 patent/WO2008093882A1/en active Application Filing
- 2008-01-30 US US12/449,255 patent/US8637079B2/en active Active
- 2008-01-30 CA CA2677201A patent/CA2677201C/en active Active
- 2008-01-30 SI SI200830149T patent/SI2107905T1/sl unknown
- 2008-01-30 PE PE2008000222A patent/PE20081663A1/es active IP Right Grant
- 2008-01-30 GE GEAP200811445A patent/GEP20125410B/en unknown
- 2008-01-30 CN CN2008800103744A patent/CN101646420B/zh active Active
- 2008-01-30 EA EA200970726A patent/EA015180B1/ru active Protection Beyond IP Right Term
- 2008-01-30 AU AU2008211981A patent/AU2008211981B2/en active Active
- 2008-01-30 PT PT08704473T patent/PT2107905E/pt unknown
- 2008-02-02 JO JO200830A patent/JO2650B1/en active
2009
- 2009-07-28 IL IL200108A patent/IL200108A/en active IP Right Grant
- 2009-07-30 TN TNP2009000317A patent/TN2009000317A1/fr unknown
- 2009-07-31 DO DO2009000195A patent/DOP2009000195A/es unknown
- 2009-08-06 MA MA32148A patent/MA31169B1/fr unknown
- 2009-08-24 CR CR10992A patent/CR10992A/es unknown
- 2009-08-31 EC EC2009009608A patent/ECSP099608A/es unknown
2010
- 2010-04-13 HK HK10103605.9A patent/HK1138188A1/xx unknown
2011
- 2011-02-07 HR HR20110094T patent/HRP20110094T8/xx unknown
- 2011-02-09 CY CY20111100150T patent/CY1111264T1/el unknown

Also Published As

Publication number	Publication date
BRPI0807453A2 (pt)	2014-05-20
UA95828C2 (ru)	2011-09-12
TN2009000317A1 (en)	2010-12-31
CN101646420B (zh)	2012-11-07
CR10992A (es)	2009-09-16
AR065097A1 (es)	2009-05-13
CL2008000279A1 (es)	2008-08-18
EP2107905A1 (en)	2009-10-14
US8637079B2 (en)	2014-01-28
JP5284968B2 (ja)	2013-09-11
MY147596A (en)	2012-12-31
EP2107905B1 (en)	2010-11-17
BRPI0807453B8 (pt)	2021-05-25
IL200108A (en)	2012-02-29
ECSP099608A (es)	2009-09-29
DE602008003522D1 (de)	2010-12-30
KR20090109115A (ko)	2009-10-19
AU2008211981B2 (en)	2012-09-20
ZA200905621B (en)	2010-10-27
TWI453041B (zh)	2014-09-21
DK2107905T3 (da)	2011-01-31
JO2650B1 (en)	2012-06-17
DOP2009000195A (es)	2009-08-31
TW201350143A (zh)	2013-12-16
PT2107905E (pt)	2010-12-17
SI2107905T1 (sl)	2011-03-31
WO2008093882A1 (en)	2008-08-07
HK1138188A1 (en)	2010-08-20
IL200108A0 (en)	2010-04-15
GEP20125410B (en)	2012-02-27
CN101646420A (zh)	2010-02-10
RS51592B (en)	2011-08-31
PE20081663A1 (es)	2008-12-25
CY1111264T1 (el)	2015-08-05
MX2009008100A (es)	2009-08-07
ES2354397T3 (es)	2011-03-14
BRPI0807453B1 (pt)	2021-01-05
US20100092551A1 (en)	2010-04-15
TW200836775A (en)	2008-09-16
AU2008211981A1 (en)	2008-08-07
HRP20110094T1 (hr)	2011-03-31
CA2677201C (en)	2015-11-17
ME01239B (me)	2013-06-20
PL2107905T3 (pl)	2011-04-29
EA200970726A1 (ru)	2010-02-26
CA2677201A1 (en)	2008-08-07
JP2010517937A (ja)	2010-05-27
ATE488227T1 (de)	2010-12-15
KR101486091B1 (ko)	2015-01-23
EA015180B1 (ru)	2011-06-30
MA31169B1 (fr)	2010-02-01
NZ579008A (en)	2012-02-24

Publication	Publication Date	Title
HRP20110094T8 (en)	2011-07-31	Solid preparation comprising alogliptin and pioglitazone
EA200800727A1 (ru)	2008-08-29	Введение ингибиторов дипептидилпептидазы
MX2007014892A (es)	2008-04-17	Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
MA30725B1 (fr)	2009-09-01	Administration d'inhibiteurs de la dipeptidyl peptidase
CY2015016I1 (el)	2016-04-13	Αναστολεις της κινασης τυροσινης του bruton
MX2007012443A (es)	2007-12-13	Formulaciones farmaceuticas orales que comprenden acido fenofibrico y/o sus sales.
ATE447568T1 (de)	2009-11-15	Neue pyrinderivate
MA31433B1 (fr)	2010-06-01	Inhibiteurs de la p70 s6 kinase
UA95199C2 (xx)	2011-07-11	Водна композиція 3-(6-(1-(2,2-дифторбензо$d]$1,3]діоксол-5-іл)циклопропанкарбоксамідо)-3-метилпіридин-2-іл)бензойної кислоти$водная композиция 3-(6-(1-(2,2-дифторбензо$d]$1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
CY2013014I1 (el)	2015-08-05	Εναντιομερικως καθαρες αμινοετεροαρυλικες ενωσεις ως αναστολεις πρωτεϊνικης κινασης
ZA200700084B (en)	2008-02-27	2,4-DI(aminopheyl) pyrimidines AS PKL inhibitors
DE602005017719D1 (de)	2009-12-31	Wässrige, flüssige Pulverformulierungen ohne Alkohol
MA30531B1 (fr)	2009-06-01	Anticorps anti-dll4 et leurs procedes d'utilisation
NO20075111L (no)	2007-11-16	Farmasoytisk sammensetning
DK1837019T3 (da)	2012-11-12	Orale dispergerbare farmaceutiske sammensætninger
FR2873585B1 (fr)	2006-11-17	Nouvelles formulations galeniques de principes actifs
HK1121955A1 (en)	2009-05-08	Lotion preparation containing pyridonecarboxylic acid derivative
EA201270204A1 (ru)	2012-08-30	Таблетка
NO20065791L (no)	2007-01-30	Asyklovir-formuleringer
DK1948126T3 (da)	2013-03-11	Oral sammensætning indeholdende morin
ITFI20080016A1 (it)	2009-08-06	Formulazioni farmaceutiche orali contenenti gliclazide.
EP1850829A4 (en)	2012-12-26	NEW PROPOLFOL COMPOSITION WITH ASCORBIC ACID OR PHARMACEUTICALLY USEFUL SALTS
CY1107277T1 (el)	2012-11-21	Βενζισοξαζολες
CR8955A (es)	2007-08-28	Hexadecasacaridos biotinilados, su preparacion y su utilizacion
TW200833325A (en)	2008-08-16	Pharmaceutical composition comprising ascorbic acid